Is infection control an academic study

Journal of Hospital Infection

Volumn 41, Issue 1, 1999, Pages 7-10

  Burnie, J P ^a  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Academic study; Infection control

Indexed keywords

ANTIBIOTIC AGENT;

ANTIBIOTIC RESISTANCE; CHLAMYDOPHILA PNEUMONIAE; EPSTEIN BARR VIRUS; HEALTH CARE COST; HEALTH CARE POLICY; HELICOBACTER PYLORI; HEPATITIS B; HEPATITIS C; HOSPITAL INFECTION; HUMAN T CELL LEUKEMIA VIRUS 1; INFECTION; INFECTION CONTROL; MORBIDITY; MORTALITY; PROPHYLAXIS; REVIEW; VACCINATION; WART VIRUS;

EID: 0032895857     PISSN: 01956701     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0195-6701(99)90030-0     Document Type: Review

References (30)

1. Wenzel RP. The economics of nosocomial infections. Journal of Hospital Infection 1995; 31: 79-87.
2. Jarvis WR. Selected aspects of the socioeconomic impact of nosocomial infections: morbidity, mortality, cost and prevention. Infect Control Hosp Epidemiol 1996; 8: 552-557.
3. Pittet D, Wenzel RP. Nosocomial bloodstream infections secular trends in rates, mortality and contribution to total hospital deaths. Arch Intern Med 1995; 155: 1177-1183.
4. Farr BM. Understaffing: a risk factor for infection in the era of downsizing? Infect Control Hosp Epidemiol 1996; 17: 150-158.
5. WHO Scientific Working Group on Monitoring and Management of Bacterial Resistance to Antimicrobial Agents. Geneva, Switzerland 1994.
6. Hiramatsu K, Anitaka N, Hanaki H, Kawasaki S, Hosoda Y. et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. The Lancet 1997; 350: 1670-1673.
7. Williams RE. Epidemiology of airborne staphylococcal infection. Bacteriol Rev 1966; 30: 660-674.
8. Edmond MB, Wenzel RP and Pasculle AW. Vancomycin-resistant Staphylococcus aureus: Perspectives in Measures Needed for Control. Annals Int Med 1996; 124: 329-334.
9. CDC. Staphylococcus with reduced susceptibility to vancomycin. MMWR Morb Mortal Wkly Rep. 1997; 46: 765-766.
10. Ploy MC, Grelaud C, Martin C, de Lumley L, Denis F. First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital. Lancet 1998; 351: 1212.
11. Burnie JP, Coke A, Matthews RC. Restriction endonuclease analysis of Aspergillus fumigatus DNA. J Clin Pathol 1992; 45: 324-327.
12. Denning DW, Clemons KV, Hanson LH, Stevens DA. Restriction endonuclease analysis of total cellular DNA of Aspergillus fumigatus isolates of geographically and epidemiologically diverse origin. J Infect Dis 1990; 162: 1151-1158.
13. Nishi J, Miyanohara H, Nakajima T, Kitajima I, Yoshinaga M et al. Molecular typing of the methicillin resistance determinant (mec) of clinical strains of Staphylococcus based on mec hypervaraible region length polymorphisms. J Lab Clin Med 1995; 126: 29-35.
14. Power EG. RAPD typing in microbiology - a technical review. J Hosp Infect 1993; 34: 247-265.
15. Loudon KW, Burnie JP, Coke AP, Matthews RC. Application of polymerase chain reaction to fingerprinting Aspergillus fumigatus by random amplification of polymorphic DNA. J Clin Microbiol 1993; 31: 1117-1121.
16. Tenover FC, Arbeit RD, Goering RV, Mickelsen PA, Murray BE et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 1995; 33: 2233-2339.
17. Tenover FC, Lancaster MV, Hill BC, et al. Characterization of Staphylococci with reduced susceptibilities to vancomycin and other glycopeptides. J Clin Microbiol 1998; 36: 1020-1027.
18. Pfaller MA. Epidemiology of fungal infections: the promise of molecular typing. Clin Infect Dis 1995; 20: 1535-1539.
19. Burnie JP, Odds FC, Lee W, Webster C, Williams JD. Outbreak of systemic Candida albicans in intensive care unit caused by cross infection. Br Med J Clin Rev Ed 1985; 290: (6470): 746-748.
20. McFarlane GA, Munro A. Helicobacter pylori and gastric cancer. Br J Surg 1997; 84: 1190-1199.
21. Prince AM. Prevention of liver cancer and cirrhosis by vaccines. Clin Lab Med 1996; 16: 493-505.
22. Mueller N. Overview: viral agents and cancer. Environ Health Prospect. 1995; 103: 259-261.
23. Kane M. Global programme for control of hepatitis B infection. Vaccine 1995; 13: S47-49.
24. Kane M. Epidemiology of hepatitis B infection in North America. Vaccine 1995; 13: S16-17.
25. Nystrom-Rosander C, Thelin S, Hjelm E, Lindquist O, Pahlson C and Friman G. High incidence of Chlamydia pneumoniae in sclerotic heart valves of patients undergoing aortic valve replacement. Scand J Infect Dis 1995; 29: 361-365.
26. Saikku P, Leinonen M, Mattila K, Ekman MR, Nieminen MS et al. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 1988; 2: 983-986.
27. Maass M, Krause E, Engel PM, Kruger S. Endovascular presence of Chlamydia pneumoniae in patients with hemodynamically effective carotid artery stenosis. Angiology 1997; 48: 699-706.
28. Juvonen J, Juvonen T, Laurila A, Alakarppa H, Lounatmaa K et al. Demonstration of Chlamydia pneumoniae in the walls of abdominal aortic aneurysms. J Vasc Surg 1997; 25: 499-505.
29. Muhlestein JB, Anderson JL, Hammond EH, Zhao L, Trehan S. et al. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation 1998; 97: 633-636.
30. Emmerson AM, Spencer RC, Cookson BD, Roberts C, Drasar BS. Diploma in hospital infection control (Dip HIC). J Hosp Infect 1997; 37: 175-180.